On a relative basis, the stock has outperformed the S&P 500 by 2.36% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.53% in the last 1 week, and is up 6.83% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.78% and the 50-Day Moving Average is 3.94%.
Edwards Lifesciences Corporation (NYSE:EW): The stock opened at $107.38 on Friday but the bulls could not build on the opening and the stock topped out at $107.60 for the day. The stock traded down to $104.92 during the day, due to lack of any buying support eventually closed down at $105.27 with a loss of -1.64% for the day. The stock had closed at $107.03 on the previous day. The total traded volume was 1,640,319 shares.
The company Insiders own 2.37% of Edwards Lifesciences Corporation shares according to the proxy statements. Institutional Investors own 87.14% of Edwards Lifesciences Corporation shares. In a related news, The Securities and Exchange Commission has divulged that Wang Huimin, officer (CVP, Japan & Intercontinental) of Edwards Lifesciences Corp, had unloaded 13,650 shares at an average price of $98.44 in a transaction dated on July 5, 2016. The total value of the transaction was worth $1,343,706.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.